Long-term intracavernous self-injection with prostaglandin E1 for the treatment of erectile dysfunction

D. Canale, P. M. Giorgi, R. Lencioni, G. Morelli, M. Gasperi, E. Macchia

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Intracavernous self-injection with vasoactive drugs has become a widely accepted treatment for erectile dysfunctions (ED). Sixty-eight patients affected by ED have been followed during long-term (at least 1 year) treatment with intracavernous prostaglandin E1. Each patient underwent a penile dynamic ultrasound examination using a high-definition probe (13 MHz) before and during the treatment. The drop-out rate was 8.8%. An improvement in spontaneous erections was reported by 13% of patients. The onset of fibrotic nodules occurred in three (4.4%) patients. In one of the latter cases the occurrence of nodules could be related to the frequency and dose of the drug administered, whereas in the other two cases no such correlation could be hypothesized. These findings draw attention to this possible side-effect of long-term treatment with PGE1.

Original languageEnglish (US)
Pages (from-to)28-32
Number of pages5
JournalInternational Journal of Andrology
Volume19
Issue number1
DOIs
StatePublished - Jan 1 1996

Keywords

  • Erectile dysfunction
  • Intracavernous treatment
  • Penile fibrosis
  • Prostaglandin E1

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Reproductive Medicine
  • Urology

Fingerprint Dive into the research topics of 'Long-term intracavernous self-injection with prostaglandin E1 for the treatment of erectile dysfunction'. Together they form a unique fingerprint.

  • Cite this